Exelixis, Inc. (EXEL)
58.39
+0.45
(+0.78%)
USD |
NASDAQ |
Oct 02, 16:00
58.37
-0.02
(-0.03%)
After-Hours: 20:00
Exelixis Price to Book Value : 7.882 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 7.882 |
| October 01, 2026 | 7.821 |
| September 30, 2026 | 7.885 |
| September 29, 2026 | 7.917 |
| September 28, 2026 | 7.879 |
| September 25, 2026 | 7.851 |
| September 24, 2026 | 7.822 |
| September 23, 2026 | 7.658 |
| September 22, 2026 | 7.850 |
| September 21, 2026 | 7.724 |
| September 18, 2026 | 7.878 |
| September 17, 2026 | 7.895 |
| September 16, 2026 | 7.665 |
| September 15, 2026 | 7.681 |
| September 14, 2026 | 7.588 |
| September 11, 2026 | 7.576 |
| September 10, 2026 | 7.752 |
| September 09, 2026 | 7.874 |
| September 08, 2026 | 7.785 |
| September 04, 2026 | 7.966 |
| September 03, 2026 | 7.982 |
| September 02, 2026 | 7.901 |
| September 01, 2026 | 7.679 |
| August 31, 2026 | 7.376 |
| August 28, 2026 | 7.350 |
| Date | Value |
|---|---|
| August 27, 2026 | 7.459 |
| August 26, 2026 | 7.573 |
| August 25, 2026 | 7.656 |
| August 24, 2026 | 7.364 |
| August 21, 2026 | 7.300 |
| August 20, 2026 | 7.248 |
| August 19, 2026 | 7.342 |
| August 18, 2026 | 7.170 |
| August 17, 2026 | 7.062 |
| August 14, 2026 | 6.917 |
| August 13, 2026 | 6.832 |
| August 12, 2026 | 6.801 |
| August 11, 2026 | 6.929 |
| August 10, 2026 | 7.149 |
| August 07, 2026 | 7.299 |
| August 06, 2026 | 7.046 |
| August 05, 2026 | 7.654 |
| August 04, 2026 | 7.559 |
| August 03, 2026 | 7.432 |
| July 31, 2026 | 7.158 |
| July 30, 2026 | 7.555 |
| July 29, 2026 | 7.469 |
| July 28, 2026 | 7.628 |
| July 27, 2026 | 7.534 |
| July 24, 2026 | 7.474 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 21.70 |
| BioMarin Pharmaceutical, Inc. | 1.750 |
| Cytokinetics, Inc. | -- |
| Emergent BioSolutions, Inc. | 0.9512 |
| Gilead Sciences, Inc. | 15.18 |
Price to Book Value Related Metrics
| PE Ratio | 18.34 |
| PS Ratio | 6.483 |
| PEG Ratio | 0.348 |
| Price to Free Cash Flow | 13.47 |
| Price | 58.39 |
| Earnings Yield | 5.45% |
| Market Cap | 14.53B |
| PEGY Ratio | 0.348 |
| Operating PE Ratio | 15.92 |
| Normalized PE Ratio | 18.05 |